| Suppression of myocardial ischemia-reperfusion injury by inhibitors of cytochrome P450 in rats. | |
| | |
MedLine Citation:
|
PMID: 19356728 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of inhibitors of cytochrome P450 on myocardial regional ischemia-reperfusion injury were examined in rats. Ischemia-reperfusion injury was evoked by ligation of the left anterior descending coronary artery for 1 h, followed by reperfusion for 24 h. Injuries were evident in causing infarction, decreases in left ventricular systolic pressure and left ventricle (dP/dt max)/P and an increase in left ventricular end-diastolic pressure. Increases in lipid peroxidation and reactive oxygen species levels in the ischemic region were observed. Intravenous injection of the potent cytochrome P450 inhibitor sulfaphenazole at 10 and 30 mg/kg at the time of reperfusion reduced infarct size by 41.7 and 73.2%, respectively; and improved cardiac function accompanied by the decrease in content of lipid peroxide and reactive oxygen species in the area at risk. Cardiac testosterone metabolism was inhibited by sulfaphenazole administration, indicating its inhibitory effects on cardiac cytochrome P450 activity. Another cytochrome P450 inhibitor, cimetidine, given intravenously, had similar effects to sulfaphenazole on reperfusion injury. Taken together, these results indicate that reactive oxygen species derived from cytochrome P450 play an important part in myocardial regional ischemia-reperfusion injury in vivo, and strongly support the hypothesis that cytochrome P450 inhibitors are promising therapeutic agents for cardiac ischemia-reperfusion injury. |
| | |
Authors:
|
Yasuhiro Ishihara; Masaya Sekine; Mikio Nakazawa; Norio Shimamoto |
Related Documents
:
|
20938668 - Ethanolamine is a novel stat-3 dependent cardioprotective agent. 16781728 - The role of natural igm in myocardial ischemia-reperfusion injury. 23061698 - A critical review of the use of carvedilol in ischemic heart disease. 15792348 - Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. 12856148 - Unilateral phrenic nerve paralysis in a patient with wegener's granulomatosis. 2968248 - Immediate ptca after successful thrombolysis with intracoronary streptokinase, three ye... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-04-05 |
Journal Detail:
|
Title: European journal of pharmacology Volume: 611 ISSN: 1879-0712 ISO Abbreviation: Eur. J. Pharmacol. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-11 Completed Date: 2009-07-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 64-71 Citation Subset: IM |
Affiliation:
|
Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences at Kagawa, Tokushima Bunri University, Sanuki City, Kagawa, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Body Weight / drug effects Cimetidine / administration & dosage, pharmacology*, therapeutic use Coronary Vessels / drug effects, injuries, metabolism Cytochrome P-450 Enzyme System / antagonists & inhibitors* Enzyme Inhibitors / administration & dosage, pharmacology*, therapeutic use Heart / drug effects Lipid Peroxidation / drug effects Male Myocardial Reperfusion Injury / drug therapy*, metabolism, pathology Myocardium / metabolism, pathology Organ Size / drug effects Rats Rats, Wistar Reactive Oxygen Species / metabolism Sulfaphenazole / administration & dosage, pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Reactive Oxygen Species; 51481-61-9/Cimetidine; 526-08-9/Sulfaphenazole; 9035-51-2/Cytochrome P-450 Enzyme System |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occ...
Next Document: Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect.